Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira agrees to $1.65 billion sale to Viatris at $36.50 per share in cash

Positive Impact 5 of 5 m&a Written later

Pacira BioSciences agreed to be acquired by Viatris through a cash tender offer at $36.50 per share, followed by a second-step merger, for an aggregate equity value of $1.65 billion. Pacira's board unanimously recommends that shareholders tender their shares, and the deal is expected to close by the end of 2026, subject to a majority tender and regulatory clearance.

Key points

  • Cash offer of $36.50 per share, with a $1.65 billion aggregate equity value
  • Tender offer to start within 15 business days of the October 8, 2026 agreement; deal expected to close by end of 2026
  • Pacira would pay Viatris a $62.0 million termination fee if it accepts a superior offer
  • Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA in the twelve months ended June 30, 2026

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECOct 8, 2026, 9:24 AM ET
Accession number0001104659-26-114571

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.